ex_132317.htm

0001437749-20-009466.txt : 20200505 0001437749-20-009466.hdr.sgml : 20200505 20200505163832 ACCESSION NUMBER: 0001437749-20-009466 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20200501 FILED AS OF DATE: 20200505 DATE AS OF CHANGE: 20200505 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: DARGAN CHARLES K CENTRAL INDEX KEY: 0001112799 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19709 FILM NUMBER: 20849521 MAIL ADDRESS: STREET 1: 8055 W. MANCHESTER AVE. STREET 2: SUITE 405 CITY: PLAYA DEL REY STATE: CA ZIP: 90293 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BIOLARGO, INC. CENTRAL INDEX KEY: 0000880242 STANDARD INDUSTRIAL CLASSIFICATION: CHEMICALS & ALLIED PRODUCTS [2800] IRS NUMBER: 650159115 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 14921 CHESTNUT ST. CITY: WESTMINSTER STATE: CA ZIP: 92683 BUSINESS PHONE: 888 400-2863 MAIL ADDRESS: STREET 1: 14921 CHESTNUT ST. CITY: WESTMINSTER STATE: CA ZIP: 92683 FORMER COMPANY: FORMER CONFORMED NAME: NUWAY MEDICAL INC DATE OF NAME CHANGE: 20030205 FORMER COMPANY: FORMER CONFORMED NAME: NUWAY ENERGY INC DATE OF NAME CHANGE: 20010815 FORMER COMPANY: FORMER CONFORMED NAME: LATIN AMERICAN CASINOS INC DATE OF NAME CHANGE: 19960520 4 1 rdgdoc.xml FORM 4 X0306 4 2020-05-01 0000880242 BIOLARGO, INC. BLGO 0001112799 DARGAN CHARLES K 18851 NE 29TH AVENUE SUITE 700 AVENTURA FL 3318 1 Chief Financial Officer Option to purchase common stock 0.14 2020-05-01 4 A 0 7500 0 A 2020-05-01 2030-05-01 Common stock 7500 3434000 D Option to purchase common stock 0.14 2020-05-01 4 A 0 214286 0 A 2020-08-01 2030-05-01 Common stock 214286 3648286 D This Option was granted to Reporting Person to replace an option to purchase 30,000 shares that had been issued approximately 10 years ago to compensate Reporting Person for services to the Issuer and had recently expired unexercised due to a discrepancy between the original exercise price and current Issuer stock price, pursuant to plan adopted by the Issuer's Compensation Committee. This amount reflects, in addition to the reported option, grant, the expiration on April 30, 2020, of an option to purchase 30,000 shares of common stock. This option vests in four equal installments every three months beginning August 1, 2020. On May 1, 2020, in recognition of recent accomplishments in response to the COVID-19 pandemic, the Issuer's Compensation Committee granted options to the Issuer's employees under the 2018 Equity Incentive Plan, including the option reported herein. /s/ John R. Browning, Attorney-in-fact 2020-05-05 EX-24 2 darganpoahtml.htm ex_132317.htm

Exhibit 24

LIMITED POWER OF ATTORNEY FOR SECTION 16 REPORTING OBLIGATIONS

Know all by these presents, that the undersigned hereby constitutes and appoints John R. Browning acting singly and with full power of substitution, the undersigned’s true and lawful attorney-in-fact to:

execute for and on behalf of the undersigned, in the undersigned’s capacity as an officer or director or both of BioLargo, Inc. (the “Company”), Forms 3, 4 and 5 (and any amendments thereto) in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the rules thereunder;

do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4 or 5, complete and execute any amendments thereto, and timely file such form with the U.S. Securities and Exchange Commission (the “SEC”) and any securities exchange or similar authority, including without limitation the filing of a Form ID or any other documents necessary or appropriate to enable the undersigned to file the Forms 3, 4 and 5 electronically with the SEC; and

take any other action in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by or for, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Limited Power of Attorney shall be in such form and shall contain such information and disclosure as such attorney-in-fact may approve in such attorney-in-fact’s discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever required, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this Limited Power of Attorney and the rights and powers herein granted.

The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request and on the behalf of the undersigned, is not assuming, nor is the Company assuming, any of the undersigned’s responsibilities to comply with, or any liability for the failure to comply with, any provision of Section 16 of the Exchange Act.

This Limited Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 or 5 with respect to the undersigned’s holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to each of the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has executed this Limited Power of Attorney as of this 14^th day of February, 2017.

/S/CHARLES K. DARGAN

By: Charles K. Dargan

Dated signed: 2/14/2017